<DOC>
	<DOCNO>NCT01588106</DOCNO>
	<brief_summary>The purpose study evaluate use CONTOUR Next USB BGMS system AutoLog Trends feature integrate data management software ( Glucofacts ™ DELUXE ) enable behavioral change may lead improvement glycemic control , express reduction HbA1c primary endpoint . Patients randomize either use CONTOUR Next USB CONTOUR . Patients train use device return every 3 month month 9 baseline .</brief_summary>
	<brief_title>Evaluation CONTOUR® USB BGMS Glycaemic Control Insulin-treated Diabetic Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Type 2 diabetes Therapy insulin ( ICT ) ICT combination Metformin HbA1c baseline &gt; 7.5 % &lt; 11 % Patients least 18 year age Patients willing complete study visit study procedure include : Testing BG least 3 time day entire study . Using paper logbook provide ( control group ) Using Auto log mealmarker + reminder feature CONTOUR Next USB regularly ( TEST subject ) Using Trends feature CONTOUR Next USB regularly ( TEST subject ) Uploading CONTOUR Next USB meter personal computer ( subject must personal computer home access computer see system requirement appendix technical detail ) . Patients able speak , read understand German Patients currently perform selftesting blood glucose home routinely ( least 3 time per day ) 4 week Patients currently adjust insulin dosage base selftesting blood glucose home Written inform consent begin study Patients use CONTOUR Next USB meter regularly previous 12 month Patients treat oral antidiabetic drug except Metformin ; diet alone Change diabetes therapy within last 3 month Change HbA1c level ±0.5 % within last 3 month Patients use continuous blood glucose measurement system regularly Patients home health aide assist BG test /or insulin adjustment Patients macroalbuminuria Steroid therapy within last 3 month . Topic inhalative use exclusion criterion use regularly ( 5 time week ) . Uncontrolled blood pressure ≥ 170/100 screen BMI &gt; 40 kg/m² Anemia accord WHOdefinition ( hemoglobin &lt; 13 g/100 ml [ male ] &lt; 12 g/100 ml [ female ] ) Creatinin &gt; 150 µmol/l and/or GFR &lt; 50 mmol/min/ 1.73m² ( measure within last 3 month screen ) Operation inpatient stay plan study Current pregnancy pregnancy plan study ; breastfeed woman . Women childbearing potential practicing acceptable method birth control . Acceptable method birth control include tubal ligation , transdermal patch , intra uterine devices/systems ( IUDs/IUSs ) , oral , implantable injectable contraceptive , sexual abstinence , double barrier method vasectomize partner Alcohol drug abuse within last 3 month Patients follow impairment , opinion investigator , would seriously compromise integrity study : Significant visual impairment Significant hearing impairment Cognitive disorder Significant unstable comorbidity ( notable change within past 3 month ) Severe renal disease , disease strong impact life expectancy Inability use computer Inability use meter correctly Any condition per investigator 's discretion Current participation another clinical study . Participation another trial within 6 week screen . Employees Bayer Vital Diabetes Care , GWT University Dresden</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>